Intranasal Ciclesonide for Treatment of Allergic Rhinitis in Children and Adolescents

M. Buck
Abstract:iclesonide nasal spray was first approved by the Food and Drug Administration (FDA) on October 20, 2006 as a hypotonic aqueous suspension (Omnaris; Sunovion Pharmaceuticals, Inc.). 1-4 It is currently indicated for the treatment of seasonal allergic rhinitis in adults and children 6 years of age and older, as well as perennial allergic rhinitis in adults and adolescents 12 years of age and older. Since its introduction, ciclesonide has become one of the most popular treatment options for allergic rhinitis, a condition affecting as much as 20% of the US population.
What problem does this paper attempt to address?